BioSpace News Archive

Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter and first half of fiscal 2020, which ended Sept. 28, 2019, are available on its Investor Relations website.

Hillrom (NYSE: HRC) today announced financial results for its fiscal fourth quarter and full year ended September 30, 2019.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2019.

Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the third quarter ended September 30, 2019,

Centene Corporation (NYSE:CNC) (“Centene”) announced today the commencement, in connection with its previously announced acquisition of WellCare Health Plans, Inc. (NYSE:WCG) (“WellCare”), of exchange offers for any and all outstanding notes set forth in the table below (the “WellCare Notes”) issued by WellCare for up to $1,950,000,000 aggregate principal amount of new notes to be issued by Centene (the “Centene Notes”) and cash.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a late-breaking oral presentation and two posters on KORSUVA™ (CR845/difelikefalin) Injection will be presented at Kidney Week 2019, the American Society of Nephrology’s Annual Meeting, to be held November 5-10, 2019, in Washington, DC.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., recognizes Familial Chylomicronemia Syndrome Awareness Day.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra® will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a formal three-year contract with Vizient Inc. effective today, November 1, 2019, to offer DEXYCU® with enhanced savings to Vizient’s diverse membership,

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has begun a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP).